Saturday, October 11, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Upgrades and Price Target Increases for Descartes Systems Group

Elaine Mendonca by Elaine Mendonca
March 7, 2024
in Breaking News
0
Biotechnology Stock Market Today (1)
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

Analyst Justin Long of Stephens & Co. has reaffirmed an Overweight rating on Descartes Systems Group (NASDAQ:DSGX) and increased the price target to $107, up from $105. This move follows previous adjustments by Stephens & Co., which also maintained an Overweight rating on the company and raised the price target from $93 to $105. Furthermore, StockNews.com recently upgraded Descartes Systems Group, raising the price target from $94 to $105 and changing the rating from “hold” to “buy”.

March 7, 2024

DSGX Stock Price Analysis: Strong Momentum Followed by After-Hours Drop on March 7, 2024

On March 7, 2024, DSGX stock showed strong price momentum as it traded near the top of its 52-week range and above its 200-day simple moving average. The price of DSGX shares increased by $2.42 since the market last closed, representing a 2.85% rise. However, despite the initial increase, the stock dropped by $4.22 in after-hours trading, closing at $87.32. The after-hours drop could be attributed to various factors, such as profit-taking by investors who wanted to lock in their gains from the day’s trading session or new information released after the market closed. Investors should continue to monitor the stock’s performance and stay informed about any news or events that may impact its price movements in the future.

DSGX Stock Analysis: Steady Performance with Consistent Revenue and Net Income Growth

On March 7, 2024, DSGX stock demonstrated a steady performance based on the financial data provided by CNN Money. The company’s total revenue for the past year was reported at $572.93 million, showing a 17.88% increase compared to the previous year. However, the total revenue remained flat at $144.70 million in the last quarter.

Similarly, DSGX’s net income for the past year was $115.91 million, reflecting a 13.37% increase from the previous year. The net income also remained unchanged at $26.60 million in the last quarter. Earnings per share (EPS) for the past year stood at $1.34, showing a 13.31% increase from the previous year. The EPS also held flat at $0.31 in the last quarter.

Overall, DSGX stock showed a consistent performance on March 7, 2024, with a stable revenue, net income, and EPS. Investors may view DSGX as a reliable investment option given its steady financial growth over the past year. However, it is essential to conduct further research and analysis before making any investment decisions.

Tags: DSGX
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Finance_Credit

Conflicting Analyst Opinions on Aris Water Solutions Price Target

SO stock news

Analyst Edward Kelly Maintains Underweight Rating on United Natural Foods Lowers Price Target

Biotechnology Market Capitalization

Analyst Upgrades Price Target for Nuvation Bio to 5

Recommended

CTVA stock news

Anticipating Acacia Researchs Earnings Report Analyst Projections and Market Trends

2 years ago
Yum China Stock

Yum China Doubles Down on Shareholder Returns Amid Market Volatility

3 weeks ago

Oppenheimer Analyst Downgrades AN2 Therapeutics Due to Trial Pause and Delay

2 years ago
Vertex Stock

Vertex Stock: Plunges Amid Pain Therapy Setbacks

2 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BigBear.ai BioNTech Broadcom Coinbase Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

UnitedHealth Faces Market Test Amid Conflicting Signals

Microsoft’s AI Breakthrough Meets Market Reality

Nvidia Shares Plunge from Record High Amid US-China Trade Tensions

Tesla Faces Triple Challenge as Regulatory Pressure Mounts

Major Eli Lilly Shareholder Initiates Significant Stock Disposal

Viking Therapeutics Stock Surges on Acquisition Speculation

Trending

Viking Therapeutics Stock
Mergers & Acquisitions

Acquisition Speculation Fuels Viking Therapeutics Stock Surge

by Andreas Sommer
October 11, 2025
0

Shares of Viking Therapeutics experienced significant upward momentum, climbing 8.1% to reach $33.90 amid renewed market speculation...

MP Materials Stock

Rare Earth Miner MP Materials Surges on Geopolitical Tensions

October 11, 2025
Advanced Micro Devices Stock

AMD’s OpenAI Partnership Ignites Stock Surge and Strategic Shift

October 11, 2025
Unitedhealth Stock

UnitedHealth Faces Market Test Amid Conflicting Signals

October 11, 2025
Microsoft Stock

Microsoft’s AI Breakthrough Meets Market Reality

October 11, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Acquisition Speculation Fuels Viking Therapeutics Stock Surge
  • Rare Earth Miner MP Materials Surges on Geopolitical Tensions
  • AMD’s OpenAI Partnership Ignites Stock Surge and Strategic Shift

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com